Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2016

Comparing African- and U.S.-Born Blacks at Stage
of Diagnosis and Treatment for Nonsmall Cell
Lung Cancer
Relindis K. Fofung
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Epidemiology Commons, and the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.

Walden University
College of Health Sciences

This is to certify that the doctoral dissertation by

Relindis Fofung

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. Donald Goodwin, Committee Chairperson, Public Health Faculty
Dr. Arti Parikh-Patel, Committee Member, Public Health Faculty
Dr. Roland Thorpe, University Reviewer, Public Health Faculty

Chief Academic Officer
Eric Riedel, Ph.D.

Walden University
2016

Abstract
Comparing African- and U.S.-Born Blacks at Stage of Diagnosis and Treatment for
Nonsmall Cell Lung Cancer
by
Relindis K. Fofung

BS, University of Calabar, 1995

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health

Walden University
May 2016

Abstract
Lung cancer is a disease with a high mortality rate for the U.S. Black population. There
had been considerable research done on different population demographics, necessary to
achieve the Healthy People 2020 overarching goals to eliminate health disparities, gain
health equity and maintain quality health. Yet, the African-born Black (AFBB)
population has been understudied for nonsmall cell lung cancer (NSCLC). This study
sought to determine whether within race differences in stage at diagnosis and treatment of
NSCLC exists between AFBB and American-born Blacks (AMBB) populations in the
United States. The study data is secondary data collected as part of the National Cancer
Institute’s Surveillance Epidemiologic and End Result (SEER) Program from 2004-2011.
Athough no significant difference was found between AFBB (n = 119) and AMBB (n =
238) relative to NSCLC stage at diagnosis, differences in treatments were found. The
proportion of AFBB patients with early stage (I and II) NSCLC who underwent surgery
differed significantly from that of AMBB (p < 0.05); AFBB patients were more likely to
receive surgical therapy. The proportion of AFBB patients with stages I-IV of the disease
who received radiation treatment also differed significantly from that of AMBB patients
(p < 0.05); the latter were more likely to receive radiation therapy. Results from logistic
regression analysis indicate that AFBB patients were more likely to receive surgical
treatment while AMBB patients were more likely to receive radiation treatment. This
study outcome can inform other NSCLC research to provide better insights to the cause
of the treatment differences within the race from differing birth places, and efficient
planning, evaluation of control programs and management of the disease.
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Chapter 1: Introduction to the Study
Problem Statement
According to the National Cancer Institute (2013f), U.S. Whites and Blacks have
marked disparities when it comes to cancer incidence and mortality. The Black
population has higher incidence and mortality rates. According to the United States
Census Bureau (2012), the Black race in the United States constitutes people born in the
United States as well as immigrants. This means that the U.S Black population is
heterogeneous in terms of place of birth.
Yet, cancer racial comparison from National Cancer Institute (2013f) does not
stratify the Black population by place of birth to determine within-race differences in
disease epidemiology that might exist. African-born Black (AFBB) immigrants constitute
part of the Black race population (United States Census Bureau, 2012) and are considered
in the comparative analyses between Blacks and Whites. Their population grew by 200%
from the 1980s through the 1990s, then by 100% from then through the 2000s to a total
of 1.1 million due to admission of large number of African refugees and the introduction
of the diversity visa program by the U.S. government (Capps, McCabe, & Fix, 2011).
Therefore, knowledge of the AFBB lung cancer epidemiology as compared to their
American-born Black (AMBB) counterpart will be of importance in effective planning,
management and evaluation of control programs of the disease for this population.
According to global cancer statistics for 2008, lung cancer was the most common
among all cancers for both males and females, accounting for approximately 12.7% of all
the cancers and 18.2% of cancer related mortalities (Ferlay et al., 2010). For males, lung
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cancer was the most common type of cancer and cancer-related mortality, with an agestandardized incidence rate of 34.0 per 100,000 population members and an age
standardized mortality rate of 29.4 per 100,000 population members (Ferlay et al., 2010).
For females, lung cancer was the fourth most common type of cancer behind breast,
colorectal, and cervical cancers. A comparison of lung cancer incidence and mortality
rates by world region showed that the age-standardized incidence rate was 13.5 per
100,000 population members, and the age standardized mortality rate was 11 per 100,000
population members (Ferlay, et al, 2010).
In addition to sex, incidence and mortality rates for lung cancer differ by
geographic region and race. According to Ferlay et al. (2010), the Middle African region
had the lowest age-adjusted incidence rates for lung cancer among all African regions
with 2.8 for males and 0.9 for females (per 100,000 population members), followed by
the Western African region with 3.1 for males and 1.2 for females. The Middle African
region also had the lowest age-adjusted mortality rates for the disease with 2.7 for males
and 0.8 for females (per 100,000 population members), followed by Western Africa with
2.9 for males and 1.1 for females (Ferlay et al., 2010; Figure 6). Meanwhile, North
America had the highest age-adjusted incidence rates for lung cancer with 48.5 per
100,000 population members for males and 35.8 per 100,000 population members for
females (Ferlay et al., 2010). The U. S. continent also had the highest age-adjusted
mortality rate from the disease with 37.9 deaths per 100,000 population members for
males and 24.2 deaths per 100,000 population members for females (Ferlay et al., 2010;
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Figure 6). This 2008 worldwide cancer statistics show that lung cancer is widely
distributed with incidence and mortality rates varying from region to region.
Analyzing data for 2001-2010, researchers at the National Cancer Institute
(2013f) reported racial and gender differences in lung cancer incidence and mortality
rates among the U.S. population. Investigators observed a higher incidence of lung cancer
among males (74.3 cases per 100,000 population members) than among females (51.9
cases per 100,000 population members). Meanwhile, the mortality rates per 100,000
population members for males of all races were 63.5; for females, it was 39.2. The
National Cancer Institute also observed gender differences for the disease within race.
Among U.S. Black males, the incidence rate per 100,000 population members was 95.8;
for Black females, it was 52.2. The National Cancer Institute (2013f) report shows that
the mortality rate per 100,000 population members for Black males was 78.5 while for
Black females was 37.2. This finding also shows lung cancer racial trends where the
incidence rate per 100,000 population members for both sexes for Whites was 63.1 and
for Blacks was 69.7 while the mortality rates per 100,000 population members for Whites
was 50.2 and for Blacks was 53.5 (National Cancer Institute, 2013f). Overall, from 20012010 in the United States, while the incidence rate for lung cancer for Black males was
almost double that for Black females; the mortality rate for Black males was more than
double that for Black females. Mortality rates for Black patients at late stage nonsmall
cell lung cancer (NSCLC) was higher than that for White patients in a study carried out
by Hardy, Xia, Liu, Cormier, Nurgalieva, and Du (2009). Yet they showed that for both
black and white patients the mortality rates were significantly reduced when stage
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specific standard therapies were received. Their study outcome underscores the
importance of comparing the incidence, mortality rates, treatments, and outcomes for
lung cancer among similar groups.
Risk Factors for lung cancer. Risk factors for lung cancer incidence. The risk factors
for lung cancer even among people of the same race have been shown to vary depending
on several factors. Etzel et al. (2008) studied lung cancer risks among African Americans
and found that exposure to air pollutants that include tobacco smoke, asbestos, wood
dusts, toluene, and xylene increased the risk for developing the disease. The researchers
found that lung cancer risk increased with duration and quantity of the tobacco smoke
exposure and the age of the individual as well as preexisting conditions such as chronic
obstructive pulmonary disease (COPD). Individuals with preexisting diseases such as
AIDS with recurrent pneumonia, and pulmonary tuberculosis, are two to five times more
likely to develop lung cancer than the general population (Shebl, Engels, Goedert, &
Chaturvedi, 2010; Hou, Fu, Ge, Du, & Hua, 2013).
The impact of differing early life experiences to lung cancer health has been
studied and documented. Early life exposure to second-hand tobacco smoke increases the
risk for lung cancer (Brown Anda, Felitti, Edwards, Malacher, Croft, & Giles, 2010).
Also, the burning of biomass or solid fuel for cooking, which is most common in
developing nations (Bonjour, et al. 2013), is a risk for lung cancer as it releases and
exposes the household to particulate matter and CO2 at a daily concentration that is
comparable to those of active cigarette smokers (Pope et al., 2009, 2011; Smith et al.,
2010). Indoor radon and workplace chemical carcinogens contribute to about 25% of all
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lung cancer cases and about 300,000 lung cancer deaths worldwide (Youlden, Cramb, &
Baade, 2008). Therefore, exposure to certain airborne pollutants is a risk for developing
lung cancer.
Lung cancer etiology and mortality perceptions and beliefs differ by race. Here,
the likelihood of Black Americans race to hold a belief that would interfere with the
prevention and treatment of lung cancer is higher than that of White Americans, OR =
2.05, 95% CI [1.19-3.53] (Lathan, Okechukwu, Drake, and Bennett,2010). The Black
American race would more likely avoid lung cancer disease screening and evaluation due
to the fear that they will be diagnosed with the disease.

Risk factors for lung cancer mortality. Lung cancer mortality rate is influenced
by several factors. Lung cancer at its earlier stage is asymptomatic, but, gradually, those
with the disease develop symptoms that are nonspecific, thus masking the cancer which
would be later diagnosed at an advanced stage of development (Youlden, et al., 2008).
Diagnosis at a late stage of the disease is the primary reason for the low survival high
mortality rates (Youlden, et al., 2008). Nonspecific symptoms coupled with lack of
adequate and qualified diagnostic health care personnel and tools contribute to late stage
diagnosis and impact the disease prognosis (Youlden, et al., 2008).
The class and stage of lung cancer which constitute the outcome variable in this
study is obtained through what is known as the tumor, node, metastasis staging, primarily
by the technique called computer tomography and positron emission tomography scans
(Mirsadraee, Oswal, Alizadeh, Caulo, & van-Beek, 2012). Furthermore, this staging
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process provides the extension of the tumor anatomy, from which the disease prognosis
and therapy are based. The two major forms of the disease are the small-cell lung cancer
(SCLC), and the NSCLC (Mirsadraee et al., 2012). While SCLC is the more aggressive
or highly metastatic form, NSCLC is of higher incidence and less aggressive consisting
of three subtypes. The three subtypes for the NSCLC are: adenocarcinoma that is often
found in the pleura or outer area of the lung; squamous cell carcinoma which forms in the
center of the lung by the bronchi; and the large cell carcinoma, which is the fastest
growing of the three subtypes, and usually forms indiscriminately in any part of the lung.
Lung cancer prognosis is very poor when it is diagnosed at an advance stage than when
diagnosed at an earlier stage. Differences in health insurance have been shown to affect
lung cancer diagnosis and care in which case the unavailability or inadequate health
insurance policies influence lung cancer mortality (Bradley, Dahman, & Given, 2008).
Studies examining risk factors have shown that high mortality rates in Blacks as
compared to Whites diminish after controlling for health insurance type (Elchoufaniz, et
al, 2013). Thus, The reasons for late stage diagnosis have been linked to several factors
that include socioeconomic status, culture, health beliefs, and preexisting lung diseases
confounding the symptoms.
African Born Population Health Studies. Health studies with African
population had been overwhelmingly involved with infectious diseases such as malaria,
tuberculosis, and HIV/AIDS, draining both resources and manpower from other disease
studies (Galukande & Kiguli-Malwadde, 2010) providing a wealth of statistics. Such
studies help reveal infectious diseases patterns for the African-born population, and guide
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policies that allow for appropriate treatment of those identified as infected, and control of
the disease. Since such intense studies have been lacking with most other chronic
diseases among which is cancer, the pattern of cancer epidemiology in Africa as well as
the African-born black immigrants to the U.S. is not well documented and is not well
understood. Thus, infectious diseases stand out as the only diseases plaguing Africans.
Claims that cancer incidence and mortality rates are high among Africans; with only
available statistics being estimated from the limited data that are collected by the sparse
urban services for cancer diagnosis, treatment, registry, as well as death registries which
serve only about 8% of the total African population (Sitas et al., 2006). Data used in
developing the cancer statistics for Africa by the International Agency for Research on
Cancer are collected by cancer registries located in 12 countries namely; Algeria, Egypt,
Mali, Mozambique, Nigeria, Senegal, South Africa, Gambia, Tunisia, Uganda, and
Zimbabwe, out of the 53 African countries (International Agency for Research on
Cancer, 2011, and United Nations, 2013a).
U S. Cancer Registries. In the United States, the contemporary estimate of
national cancer statistics is provided through the Surveillance, Epidemiology, and End
Results (SEER) program. Created by the National Cancer Institute (NCI), it consists of
18 registries located in 14 states (Alaska, Arizona, Connecticut, Michigan, Georgia,
California, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Washington,
and Utah; National Cancer Institute, 2013a). Its website contains data on race, date of
birth, sex, stage and age at diagnosis, treatment type, place of residence, marital status,
country, and state of birth from the cancer surveillance reports for patients diagnosed
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with cancer (National Cancer Institute, 2013d, and 2013e).These registries account for
about 28% of the U.S. population and include 26% of its Black population. The
population that the SEER program covers compares to the general U.S. population in
terms of poverty and education level, and consists of a higher proportion of foreign-born
persons (National Cancer Institute, 2013a, 2013b, 2013c). For the purpose of lowering
cost and improving quality and consistency of data collected, all the registries are
supported by a centralized data management system (National Cancer Institute, 2013a,
2013b, 2013c). Thus, the U.S. centralized system of cancer registries provides a unified
method of collecting and managing cancer data.
African Registries. African countries participating in the World Health
Organization (WHO) cancer data collection lack a unified authoritative cancer registry.
Unlike the United States where all 14 participating states operate cancer registries under a
unified central organization, SEER, those countries in Africa from which WHO gathers
data used for world cancer statistics operate their own independent cancer registries. The
few African countries that operate their own cancer registries are Algeria, Egypt,
Gambia, Mali, Mozambique, Nigeria, Senegal, South Africa, Tunisia, Uganda and
Zimbabwe (International Agency for Research on Cancer, 2011).
Dependence on anecdotes is insufficient in determining how lung cancer
epidemiology for the African-born Black subgroup compares with the American-born
Black subgroup. Most health studies for population subgroups are usually unavailable
because of the difficulties with appropriate and sufficient data collection, the cost,
manpower and time. Cancer, including lung cancer data for the African-born Blacks in
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the U.S is readily available through the SEER program and is used only when considered
in African American cancer epidemiologic studies. The data include variables such as
cases’ race, sex, age, place of birth, and type, stage and date of cancer diagnosis,
treatment type received as well as the disease outcome (National Cancer Institute, 2013d,
and 2013e) that can be used to generate cancer statistics on a sample of African born
Black population. One of the cancers showing the highest incidence and mortality
disparity between the White and Black populations is lung cancer (National Cancer
Institute, 2013f). It therefore gives a great opportunity to examine whether there are any
differences in the stage at which the cancer is diagnosed and the type of treatment
received between the Black populations of African and American nativities in the United
States. Therefore, in this study, I seek to determine whether there is any difference in the
stage at diagnosis and the type of treatment received for NSCLC among AFBB and
AMBB populations in the United States.
This type of analysis requires the disease incidence cases to serve as the
population under study. The World Health Organization collects cancer data from
different countries in the world using standardized methods (International Agency for
Research on Cancer, 2013a). These data have been used to study the global epidemiology
of cancers, including lung cancer, providing countries’ cancer incidence and mortality
rates to the International Agency for Research on Cancer (IARC) for their GLOBOCAN
publication (Ferlay, Shin, Bray, Forman, Mathers, & Parkin , 2010; International Agency
for Research on Cancer, 2013b). Sources for mortality data include cancer registries, vital
records, and verbal autopsy surveys. Then for incidence rates, the WHO obtains
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countries’ data by: (1) high quality regional data classified in 3 alpha numeric categories
as A, B, and C according to the percentage of the cases that it covers which are
respectively: greater than 50%; between 10% and 50%; and lower than 10%; (2) National
data or category D; (3) Regional data or category E; (4) Frequency data or category F;
and (5) no data or category G. According to the type of data available, various methods
are used to estimate each country’s incidence and mortality rates. These methods include:
rates projection to 2012, applying most recent rates to the 2012 population, estimates
using modelled survival, using weighted average of the local rates to estimate the national
rate, use of data from a single cancer registry or use of the weighted average of local
rates, and the use of neighboring countries’ rates or data to estimate another country’s
rates (International Agency for Research on cancer, 2013b). The data source and methods
outlined by International Agency for Research on Cancer, (2013b) indicate that data from
the United States fall in category A and it covers more than 50% of the cancer cases; but
most African countries (including Angola, Burundi, Cameroon, Cape Verde, Central
African Republic, Chad, Congo, Democratic Republic of Congo, Cote d Ivoire, Ethiopia,
Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Mali, Morocco,
Mozambique, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Tanzania,
Togo, Uganda, Western Sahara and Zambia) fall in categories E, F and G for which data
availability is less than 10% or is not available at all, while the only high quality data
from Africa come from Egypt, Uganda and Zimbabwe that fall under category C.
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Nature of the Study
I will use a retrospective study design using secondary data acquired from the
SEER database, the underlying cancer data source for the study. For this study, the
frequency data for lung cancer from 2004-2011 for Black cases of American and African
nativities shall be obtained from the SEER database using Black race, place of birth and
NSCLC as filters for the specific states that operate a SEER Cancer Registry. The queried
data shall be edited to make sure that only patients with information that include the age,
gender, the NSCLC stage at diagnosis, treatment type as radiation and surgery, shall be
selected for the study. The Statistical Packages for the Social Sciences (SPSS) or the Epi
Info software shall use to perform the necessary data analysis.
Research Questions and Hypotheses
I will use the following research questions to guide my investigation.
RQ1: Among Black patients newly diagnosed with NSCLC and reported to SEER
between 2004 and 2011, do the proportions of NSCLC stage (I, II, III and IV) differ
significantly between AFBB and AMBB patients?
RQ2: Among Black patients diagnosed with early stage (I, II) NSCLC and reported to
SEER between 2004 and 2011, does the proportion of AFBB patients who underwent
surgery differ significantly from the corresponding proportion of AMBB patients?
RQ3: Is there any significant difference in the proportion of AFBB NSCLC (stages I, II,
III and IV) patients treated with radiation to the corresponding proportion of AMBB
patients, reported to SEER from 2004-2011?
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RQ4: Among Black early stage (I, II) NSCLC patients reported to SEER between 2004
and 2011, does the proportion of AFBB patients who received neither surgery nor
radiation differ significantly from the corresponding proportion of AMBB patients?
The null hypothesis is that between the African-born and American-born Black
populations living in the U.S., there are no differences in their NSCLC stage at diagnosis
and the type of treatment they receive for the years 2004-2011. This retrospective study
will utilize secondary analysis of quantitative data. With funding from the National
Cancer Institute (NCI) the SEER program has created cancer registries around the United
States that cover about 28% of the national population. These authoritative data sources
provide data with variables that include the cases’ age, sex, date of birth, place of birth,
race, geographic area, cancer type, and year of diagnosis are collected and submitted to a
unified database maintained by SEER (National Cancer Institute, 2013a, 2013b, and
2013c).
Theoretical Framework
I will draw from Ecological Theory which says that the ecology involved in
human development describes that science which deals with the growing human’s
exposure or active engagement in the properties of the changing living environment, as
well as their larger interconnecting settings (Bronfenbrenner, 1979). The environment in
this context involves the immediate as well as the wider society that include
governmental policies, culture and economic structures, that shape the growing person’s
psychology, social and biological development (Bronfenbrenner, 1979, p. 21).
Researchers have shown that adverse childhood experiences lead to increased risk for
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lung cancer (Brown et al., 2010). To support this childhood experience risk factor,the
effect of place of birth was shown to be a factor that influenced the receipt of breast
cancer surgery when Chavan,Goodman, Jemal, & Fedewa (2014) compared U.S. resident
breast cancer women born in 6 different countries. The theory held true after controlling
for several covariates. Place of birth was the only variable that was linked to the observed
outcome that showed within-race differences in which Foreign-born Asian women
received less breast cancer surgery when compared to their counterpart American-born
Asian women, as well as Non-Hispanic White women with OR of .76 at 95% and CI =
.72 – 0.80. In another study the incidence rate of NSCLC is shown to be approximately
35% higher for foreign born Asians than U.S. born Asians living in the State of
California. This NSCLC incidence pattern by nativity is consistent with the populations’
tobacco smoking prevalence (Raz, Gomez, & Chang, 2008). Following these
observations, whether place of birth influences the NSCLC stage at diagnosis as well as
the type of treatment received by AFBB compared to their counterpart AMBB cases will
be determined by the data analysis.
Types and stages of lung cancer and treatment options.
The SEER cancer staging manual requires lung cancer to be classified into the different
types of tumors that are found. But, these different tumors fall under two main categories;
the small cell lung cancer (SCLC) and the non-small cell lung cancer (NSCLC) (National
Cancer Institute, 2013d, 2013e, and 2014f). The stage at diagnosis for lung cancer
specifically applies to one type, the non-small-cell lung cancer (NSCLC) which
constitutes a significantly higher incidence of all lung cancers cases (Mirsadraee, et al,
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2012). It is detected at five major stages namely: occult or stage 0, stage I, stage II, stage
III and stage IV and thus reported as required by the SEER Program coding and staging
manual, though the numbers diagnosed with stage 0 is usually too small to be considered
in statistical analysis (National Cancer Institute, 2013d, and 2013e, and 2014f).
Meanwhile, there are 5 major types of treatments possibilities for lung cancer and are
namely: no treatment, surgery, radiation, chemotherapy and others to include
experimental methods. Of these treatments, chemotherapy is only applied to SCLC
though it is usually diagnosed at very advanced stage, unsuitable for surgery. Meanwhile
NSCLC does not respond to chemotherapy and so is not reported to SEER. But, the
earlier stages (I and II) are curable by surgery and radiation since they are localized.
Meanwhile, the late stages (III and IV) are not suitable for surgery but do get radiation
for palliative purposes (National Cancer Institute, 2014f).
Significance of the study
This study is basically an evaluation of the effect of birth place on the stage (I, II,
III and IV) at which non-small cell lung cancer is diagnosed; and the type of treatment
(no treatment, surgery or radiation therapy) received between U.S. resident AFBB and
AMBB lung cancer patients. Between U.S and Africa, differences in the rate of
screening, health services availability, treatment, follow-up care, and record keeping do
exist. Therefore, it is best to compare data from samples of the two populations when
they are living in the same environment where the opportunity for screening, treatment,
care, record keeping and environmental conditions are more similar than when they are
living in separate continents. According to the ecological theory on which this study is
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based, these factors constitute the ecological factors that affect the wellbeing of an
actively growing child (Bronfenbrenner, 1979) and so studying their effects on disease
outcome in different populations can help detect where help is needed.
Implications for Social Change
This may help fulfill the goal of reducing cancer disparity for population groups
as required by the Healthy People 2020 overarching goal (United States Department of
Health and Human Services, 2010 and 2013). This study has a great potential for a social
change. The study outcome could indicate whether there is a significant difference in the
proportions of lung cancer stage at diagnosis, and treatment between of AFBB and
AMBB NSCLC patients. Also, it could be a basis for in-depth investigation to
understand each group’s cultural, social, belief system, and ease of access to prevention
education and treatment, all of which could be potential reasons why such differences
were observed. This could aid in the development and implementation of interventions
that may influence cultural, social and behavioral modifications that can in turn
encourage early diagnosis for the population that is more at risk for late stage NSCLC
diagnosis. This will help to appropriately achieve the goal of the Healthy People 2020, in
the context of lung cancer that seeks to eliminate health disparities, gain health equity and
maintain quality health for different population groups through the assessment of various
demographics such as race/ethnicity and geography (United States Department of Health
and Human Services, 2010, and 2013). The study outcome will also be a key source of
information to Africans seeking knowledge about African immigrant lung cancer
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statistics as well as providing research opportunities to interested epidemiologists wishing
to examine the risk factors that influence such within-race disparities.
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Chapter 2: Literature Review

In this chapter I will discuss research literature for lung cancer risk factors, incidence
rates, treatment methods, mortality rates and stages at diagnosis for better understanding
of the sample used and interpretation of the study findings. The review is subdivided into
the literature search, epidemiological timeline of lung cancer, lung cancer risk factors,
incidence and mortality

Research Literature Search
I searched for full-text research literature by using the major biomedical research
databases PubMed Central, PLos One, the CDC’s Mortality Morbidity and Mortality
Weekly Report database, and the National Library of Medicine. I also searched Google
Scholar. The NCBI database includes titles such as Journal of Cancer Epidemiology,
Journal of Clinical Oncology, Journal of Thoracic Oncology, CA: A Cancer Journal for
Clinicians, Journal of the National Cancer Institute, , and Journal of Biomarkers &
Prevention. I restricted my search to articles published within the past 5 years.
I reviewed references in the articles I found for other relevant research. I found no
primary research articles comparing lung cancer incidence and mortality and the stages at
diagnosis as well as the treatment type received among AMBB and AFBB. Instead, the
majority of the articles that I found concerned lung cancer risk factors; a few were
epidemiological studies. I selected a total of 120 articles of much relevance to my
research questions from the total of 8,803 that my general search returned. I further
screened the 120 research articles for those with free access to the full text, and contacted
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the Walden University Library for help with access to those with restricted access.
Meanwhile I excluded some that were too recent and did not yet have any access from the
literature review.
Epidemiological Trend and Evidence of the Etiology: The Timeline
Lung cancer and tobacco smoke. Researchers began to describe malignant
growth of the lung and bronchi and the possible etiology in the early 1900s. Adler (1912)
reviewed hundreds of autopsy and pathology reports in Europe and the United States. He
found an association between malignant growths of the lung and tuberculosis and
suggested that subjects’ occupation and tobacco smoking might also be involved (Adler,
1912).
After Adler’s (1912) report, there were reports of noticeable increase in the
incidence of lung cancer in England and Wales from 1921-1932 where the absolute
number of lung cancer cases rose from 361 cases in 1921 to 2095 cases in 1932 for men
and from 186 cases in 1921 to 680 cases in 1932 for women (Kenneway & Kenneway,
1936). The death ratio for women increased from 1:1.94 in 1921 to 1:3.08 in 1934
(Kenneway, & Kenneway, 1936). Clinically and statistically, Wynder and Graham (1950)
demonstrated tobacco smoking as the major contributing factor to this rapid increase. In
the cases that they analyzed, Wynder and Graham assessed individuals’ occupations,
history of previous lung disease, hereditary components, and smoking habits.
The researchers Wynder, & Graham (1950) found out that 98.7% of the 605 cases
involved in their study were smokers. Following Wynder & Graham (1950) finding, Doll,
& Hill (1950) conducted a study involving a much larger participants pool made up of
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1731 lung cancer cases, and control consisting of 1762 patients with cancer-of-othersites, respiratory and other diseases in England. The Doll, & Hill (1950) study
participants were from varied residential cities but had similar access to medical care.
Doll & Hill (1950) assessed their smoking history and habits in many different scenarios
after eliminating sampling errors and interviewer bias. They considered estimated amount
of tobacco that the subjects regularly and recently smoked before illness onset, the
approximate maximum amount of tobacco smoked on a daily basis, and the approximate
total smoked since starting to smoke. Doll & Hill (1950) then compared lung carcinoma
patients and the study control group for each of these three scenarios. They found that
heavy smokers made up a significantly larger proportion in the lung carcinoma group;
26.0 % men and 14.6% women regularly smoked 25 or more cigarettes a day as
compared to 13.5% men and 0% women in the control group. From their results, they
concluded that carcinoma of the lung patients smoked the maximum amount for each
scenario than the control, indicating that smoking might have played a role in causing
their lung cancer (Doll & Hill (1950). Their study therefore showed that cigarette smoke
causes lung cancer.
Doll and Hill as well as other researchers continued to study the association
between tobacco smoke and lung cancer, and in 1954 they initiated a prospective study
involving 40,564 British mmedical ddoctors as the study subjects (Doll & Hill, 1954).
They stratified the subjects during the baseline data collection into continuing smokers,
ex-smokers, and never-smokers. They observed at intervals the subsequent changes in
smoking habits and lung cancer mortality, as well as other diseases for the study subjects.
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Lung cancer death rate increased as the amount of cigarette smoked per day increased
after 29 months observation (Doll & Hill, 1954). The lung cancer death rate for
nonsmokers was 0.00 per 1000 population, while for those who smoked at least 25g of
tobacco or more daily was 1.14 per 1000 population (Doll & Hill, 1954). After 10 years
observation, the death rate from lung cancer for continuing smokers doubled that for
nonsmokers (Doll & Hill, 1964).
In 1965, Hill compared their findings to that of the report of a study that was done
several decades earlier involving scrotal cancer and its association to chimney sweeping
(Waldron, 1983; Hill, 1965). He found a similarity in association between each disease
and the environmental factors to which those patients were exposed (Hill, 1965). After
elimination of chance occurrence, and despite these strong associations observed between
lung cancer and smoking; and scrotal cancer and chimney sweep, to conclude that such
environmental factors caused the diseases Hill (1965) pointed out a number of aspects of
such associations that must be fulfilled. In his address to the Royal Society of Medicine
during a meeting, Hill (1965) using the results of their tobacco smoking and lung cancer
studies indicated that causation can only be concluded from (1) the strength of the
association between the disease and the factor in question in which case such an
association must be in excess when compared to the disease association with other
possible causes, (2) consistency of such an association, in which case the same result
must be obtained if the study is repeated by different researchers at different times and
locations, (3) specificity of association in which instance the association must be limited
to a particular disease and population at a particular place, where no excess of the disease
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is observed without the presence of the factor in consideration, exemplified by the results
of the smoking and lung cancer study results (Doll, & Hill, 1964), (4) temporality of
association in which case the exposure to the factor must occur before the onset of the
disease; (5) Biological gradient exemplified by the fact that in their study, lung cancer
death rate rose linearly with increase in amount of cigarette smoked; (6) plausibility; (7)
coherence exemplified by the fact that the association between lung cancer and cigarette
smoking has been coherent with the histopathology results for the disease in such
patients; (8) experiment which he exemplified by the fact that if cigarette smoking is
eliminated, will the association between it and lung cancer reduce; and (9) analogy where
the effect of similar factors leading to the same kind of association should be considered
(Hill, 1965). These have since been known as the Bradford Hill Criteria for causation and
are widely applied in epidemiological investigations of causality.
During the 20th year Doll and Hill observation of the study population showed
tobacco consumption had markedly reduced, and lung cancer death rate also reduced, but
death rate from other diseases did not reduce accordingly (Doll, Peto, 1976). By the 40th
year those who ceased smoking by middle age had substantially low risk of dying from
lung cancer as compared to those who continued smoking (Doll, Peto, Wheatley, Gray, &
Sutherland, 1994)
With these revelations, studies focused on tobacco smoking have revealed its
trend and relation to other diseases, including lung cancer incidence and mortality. In the
United States, stratifying study cohorts by time periods as 1960s, 1980s and
contemporary (2000s) in the comparison of those who smoked to those who never
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smoked, showed the relative risks of death from lung cancer in women to be 2.73, 12.65,
and 25.66 respectively, and in men to be 12.22, 23.81, and 24.97 respectively (Thun, et
al 2013). In 2009, the prevalence of cigarette smoking among adult US population 18
years and older was 20.6% with prevalence of 23.5% for men and 17.9% for women
(Centers for Disease Control and Prevention, 2010). For the 5 years period, from 20052009, there was no significant difference in cigarette smoking prevalence which was
recorded at 20.9% and 20.6% respectively for U.S adults 18 years and older (Centers for
Disease Control and Prevention, 2010).
Tobacco use is also common in Africa, exemplified by Ghana, a West African
nation where studies have shown that smoking intention among the youths were 27.7%
for those exposed to tobacco smoking commercials as compared to 19% for those not
exposed to such commercials (Doku, Raisamo, & Wiium, 2012). Among Ghanaian
adolescents 14-19 years old, tobacco smoking prevalence of 1.0% was lower when
compared with the older adults 60-69 years with prevalence of 6.1% (Owusu-Dabo,
Lewis, McNeill, Gilmore, & Britton, 2009, Table 2). But, a later study showed the
average daily smoking prevalence among the older adults estimated at 7.6%; meanwhile,
the prevalence among men was higher at 11.3% as compared to female with 3.7%
(Yawson, et al., 2013, Table 1). The countries, Rwanda, Uganda , Tanzania and Kenya,
all located in Eastern Africa have the highest prevalence of cigarette smoking among men
of 14.2%, 18.7%, 21.0%, and 22.9% respectively, with the lowest prevalence of 8.0%
seen in men of the Western Africa state of Nigeria (Pampel, 2008).
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Lung cancer in never-smokers.
Preexisting diseases as lung cancer risk factors. Despite the compelling
evidence that has linked tobacco smoking to lung cancer incidence and mortality since
the early 20th Century to contemporary times (Wynder, & Graham, 1950; Doll & Hill,
1950, and Thun, et al, 2013), nonsmokers have other lung cancer risk factors too. These
include environmental air pollutants and previous inflammatory lung disease (Samet,et al,
2009, and Moldoveanu et al, 2009 ). Common among the inflammatory lung diseases
which could also be seen in smokers are tuberculosis, emphysema, pneumonia and
chronic bronchitis. But independent of tobacco smoking these conditions have been
studied by the International Lung Cancer Consortium and shown that the relative risk for
them to influence lung cancer are 1.48 (95% CI: 1.17-1.87), 2.44 (95% CI: 1.64 - 3.62),
1.57 (95% CI: 1.22 - 2.01), and 1.47 (95% CI: 1.29 -1.68) respectively (Brenner, et al.,
2012). In a tuberculosis study cohort, 26.3 per 100,000 persons of patients with
tuberculosis developed lung cancer; which is 10.9 times more, compared to the 2.41 per
100,000 persons for non-tuberculosis patients who developed lung cancer (Yu, et al.
2011). Another preexisting disease, HIV infection, is also a risk factor for lung cancer
with an incidence relative risk of 1.7 (95% CI: 1.5 to 1.9) after 37,294 HIV positive U.S
Veterans and 75,750 uninfected controls, composed of about 50% non-Hispanic African
Americans and 40% non-Hispanic Whites were followed for 5.8 years in a prospective
cohort study (Sigel, et al., 2012).
Environmental Air pollutants. Apart from preexisting diseases, chronic and acute
exposure to some ambient air pollutants increases the risk for lung cancer (Turner, et al.,
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2011). One such air pollutant is silica and those exposed to it have a lifetime risk of
0.51% for lung (Liu, et al., 2013). Nitrogen oxides derived from traffic is also associated
with lung cancer with incidence relative risk (IRR) of 1.30 (95% CI: 1.05–1.61),
(Raaschou-Nielsen, et al., 2011).
Incidence and mortality. In South Africa, for the general population, the annual
lung cancer mortality did not significantly change as it only minimally decreased from
24.3 per 100,000 population in 1995 to 23.8 per 100,000 population in 2006 (Bello,
Fadahun, Kielkowski, & Nelson, 2011). But, by gender, for corresponding years, the rate
increased for women from 10.8 per 100,000 populations to 13.4 per 100,000 populations,
though it decreased minimally for men from 44.2 per 100,000 populations to 39.4 per
100,000 populations (Bello, et al., 2011). However for the general South African
population, there was a significant change for the 5 years’ time frame of 2000-2005 with
an annual decrease of 129 deaths per 100,000 populations though from 1999-2006 there
was a significant annual increase of 0.34 per 100,000 populations for women (Bello, et
al., 2011).
Even though 1 out of 4 men in the East African country of Malawi smoke tobacco
(Msyamboza, et al., 2011), a study of cancer burden in the country revealed that the least
common cancer was lung cancer, and it accounted for only 0.2% of the 18,946 new
cancer cases that were registered from 2007-2010 (Msyamboza, et al., 2012). A
retrospective study spanning 15 years (1993-2007) identified 1,882 registered lung cancer
cases in the North African nation of Tunisia which accounted for 10.9% of all the cancers
registered during that period for the general population, but it contributed for 21.7% of all
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cancer cases registered for men, and 1.4% for women (Missaoui, et al. 2011). The trend
for lung cancer in Tunisia during the study period decreased significantly by - 6.5% (95%
CI: -12.9% to - 0.2%), (Missaoui, et al. 2011).
In a comparison of U.S non-Hispanic Black and White population aged 20 to 39
from 1992-2006 the death rate from lung cancer per year decreased by 3.6% in white men
and 7.9% in Black men, meanwhile, the decrease was 1.9% in White women and 4.8% in
Black women (Jemal, Center, & Ward 2009). There has been a marked reduction in the
prevalence of tobacco smoking in the United States, more so for women and men of the
West with average of 33.3% and 28.5% respectively while the smallest decrease is in the
Midwest with 20.3% and 18.6% respectively (Jemal, et al., 2011). Yet, in most U.S.
States, lung cancer mortality rates for White women have been on the rise except for
California where there has been a decline (Jemal, et al., 2012).
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Chapter 3: Research Method

In this chapter I will discuss the study objectives, research questions, and hypotheses. I
will also describe the study method to provide a clear understanding of the research
questions and hypotheses, the methods that I will use to obtain the data, the sample size
calculation and instrumentation, as well as the statistical test methods for the data
analysis.
Study Objectives
Reflecting on this within-race study, as stated in the research questions below the
objective is two folds. Firstly, the objective is to gather lung cancer data collected from
2004-2011 for AFBB and AMBB; and secondly, to use the acquired data to answer the
research questions (RQ) following the stated hypotheses (H0) and alternative hypotheses
(H1). The populations in the study are AFBB and AMBB who have been diagnosed as
having NSCLC, and recorded in the SEER database.
Research Questions, Hypotheses, and Alternative Hypotheses.
I used the following research questions to guide my investigation:
RQ1: Do the proportions of NSCLC stage (I, II, III and IV) in the SEER database
for 2004-2011 differ between AFBB and AMBB patients?
H01: There is no significant difference between the proportion of AFBB and
AMBB diagnosed with NSCLC by stage (I, II, III and IV) and reported to SEER between
2004 and 2011.
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H11 There is a significant difference between the proportion of AFBB and AMBB
diagnosed with NSCLC by stage (I, II, III and IV) and reported to SEER between 20042011.
RQ2: Among Black patients diagnosed with early stage (I, II) NSCLC reported to
SEER between 2004-2011, does the proportion of AFBB patients who underwent
surgery differ from the corresponding proportion of AMBB patients?
H02: There is no significant difference between the proportion of AFBB early
stage (I, II) NSCLC who underwent surgery and the corresponding proportion of AMBB
patients that were reported to SEER between 2004-2011
H12: There is a significant difference between the proportion of AFBB early stage
(I, II) NSCLC who underwent surgery and the corresponding proportion of AMBB
patients reported to SEER between 2004-2011
RQ3: Is there a significant difference in the proportion of AFBB NSCLC (stages
I, II, III and IV) patients treated with radiation to the corresponding proportion of AMBB
patients, reported to SEER from 2004-2011?
H03: The proportion of AFBB NSCLC (stages I, II, III and IV) patients treated
with radiation differs from the corresponding proportion of AMBB patients, reported to
SEER from 2004-2011.
H13: The proportion of AFBB NSCLC (stages I, II, III and IV) patients treated
with radiation differs from the corresponding proportion of AMBB patients, reported to
SEER from 2004-2011.
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RQ4: Among the early stage (I, II) NSCLC patients reported between 2004 and
2011, does the proportion of AFBB patients who received neither surgery nor radiation
differ significantly from the corresponding proportion of AMBB patients?
H04: The proportion of AFBB early stage (I, II) NSCLC patients who received
neither surgery nor radiation does not differ significantly from the corresponding
proportion of AMBB patients, reported between 2004-2011.
H14: The proportion of AFBB early stage (I, II) NSCLC patients who received
neither surgery nor radiation differs from the corresponding proportion of AMBB
patients, reported between 2004-2011; there is no significant difference in their
proportion
Research Population and Setting.
Based on my research questions and hypotheses, I limited eligibility of
participants to patients who are Black and who were born in the United States or an
African country or region. I excluded cases with unknown values for age, gender, stage at
diagnosis, marital status, country of birth, radiation, and surgical treatment methods.
Sample Size Determination. For this retrospective study, I determined the
sample size using the Open Epi software calculator. I was interested in analyzing both
male and female AFBB and AMBB cases. I based my sample size on a number of risk
ratios (1.2, 1.5, and 1.75), a 95% CI, and the chance of detecting a meaningful outcome
or the conventional statistical power for the study at least 80% (Fosgate, 2009). From
information gathered from the Georgia Comprehensive Cancer Registry (GCCR), one of
the SEER Program Registries, the ratio of AFBB lung cancer cases to AMBB lung cancer
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cases is approximately 1:20. I used this ratio in the Open Epi software calculator for the
“Ratio of unexposed to exposed” in the sample size calculation. For the pair of sample
size calculation done, the percent of exposed with outcome is assumed at four possible
values being 20%, 30%, 40%, and 50%; and the risk ratio at three different levels being
1.2, 1.5 and 1.75. I used these figures in order to generate a wide range of eligible cases
within which to choose the best sample size. Table 1 shows the sample size ratio for
AFBB to AMBB patients with lung cancer. The ratio ranges from a low of 15:293 to a
high of 850:16984.

Table 1 Sample Size Ratios for Lung Cancer AFBB to AMBB Subjects
% Unexposed with
outcome

RR=1.2

RR=1.5

20
850/16984
136/2713
30
491/9810
78/1557
40
317/6332
50/997
50
207/4121
33/669
Note. Assumptions: power = 80%, two sided type error = 0.05
RR is Risk ratio

RR=1.75
61/1210
35/697
23/445
15/293

This AFBB to AMBB ratio of 1:20 calculated using the original sample presents a very
wide size discrepancy which will inevitably influence a significant difference in the
calculated proportions. Therefore, from the AMBB population a random sample shall be
approximated to reduce the sample size ratio to 2 AMBB: 1 AFBB. In this process,
patients’ age and gender which are confounding variables to the dependent variables shall
be used to determine the sampling method for selecting the AMBB study sample. One of
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two possible methods shall be used depending on the outcome of the preliminary
population age and gender proportion comparisons for the two groups. If the population
age and gender proportions comparisons yield a significant difference, between AFBB
and AMBB, then from the unsorted AMBB original population, a number of cases that
double the number of AFBB shall be selected from the top of the list. A second method
of sampling if the preliminary population age and gender proportions comparison for
AFBB and AMBB do not yield any significant difference will be purposive sampling. In
this case 2 AMBB subjects shall be matched to 1 AFBB for all the AFBB subjects, by
age and gender.
SEER data source. The required secondary data variables for this study are all
included in the SEER primary data information collected, which fall into 3 categories: (1)
Cancer identification which include the primary site, stage, diagnostic procedure and
date; (2) patient demographics to include the race, gender, age, and birth place, but void
of personal identifiers; and (3) NSCLC disease treatment and outcome of the patients
(National Cancer Institute, 2014b).
Ethical consideration. For the SEER Program, patient confidentiality is highly
respected during primary data collection. The gathering, reporting and accessing of the
data are guided by specific laws, and are only allowable to eligible individuals (National
Cancer Institute, 2014c). Furthermore, personal identifiers are coded before any
transmission is done (National Cancer Institute, 2014c). Thus, the data for this study shall
contain assigned or coded identities for each patient, rather than specific patient’s
identifiers. To further protect the patients’ privacy, during abstracting of the lung cancer
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data for this study, the SEER database shall be accessed following stipulated guidelines
and permission from the SEER Program. According to the SEER Program website,
among all the primary data information collected, some basic ones such as cancer type
and stage, date of cancer diagnosis, race, sex, age, type of treatment, and the date and
status of last follow up are readily available to be abstracted (National Cancer Institute,
2014d). Among these available information those appropriate to create the NSCLC study
frequency data shall include the Black race cases, the year of diagnosis, sex, age, place of
birth, treatment received, and marital status. The country of birth shall be decoded, and
for those born in Africa, selection shall go by names of specific countries as well as the
African Region (Northern, Southern, Middle, Eastern and Western Africa). For those
born in the United States, all the SEER’s State-of-birth codes (National Cancer Institute,
2014e) shall be recoded to the one code assigned to the country of birth as the United
States of America (U.S.A.); then the SEER’s Government Services Administration codes
for African Country of Birth (National Cancer Institute, 2013, and National Cancer
Institute, 2014e). These abstracted data shall be presented in a table, void of personal
identifiers; and, being a secondary data analysis, there shall be no direct contact with the
involved subjects.
Statistical Analysis of Data
For the data, the total number of NSCLC cases will serve as the subjects under
study. Then, the data analysis shall be performed using the Statistical Package for the
Social Sciences (SPSS) software (IBM Corporation, 2014). The statistical test to answer
each of the four questions RQ1 through RQ4 will be the Chi-square test; and each p-
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value obtained compared to the alpha (0.05) to determine whether or not to reject the null
hypothesis. This statistical test is suitable because each of the questions involves the
difference between 2 groups only. The categorical independent variables is place of birth
of Black race (represented by AFBB and AMBB), and the dependent variables are the
stage-at-diagnosis of NSCLC; and the type of treatment received. The assumption here is
that for each of the research questions, the 2 sets of samples are random and independent;
and that the 2 populations from which the 2 groups, AFBB and AMBB NSCLC cases are
derived are normally distributed. It is also assumed that the test is going to be a 2-tailed
test, meaning that there will be two rejection regions, one on each tail of the assumed
normal distribution. This software comparison of the 2 groups’ proportions using the Chi
square test will yield the p (or 2-tailed significance) values from which the 2 samples
proportions differences can be interpreted by comparison to the critical p-value. Other
possible predictors of the outcome under study include age, and marital status which can
be possible confounding variables. For any of the Chi square tests that show a significant
difference between the two groups, a logistic regression analysis shall be performed. For
this test, the study subjects’ ages gender and the marital status shall be used as covariates
to the place of birth.
Study Limitations. The potential limitations to this study will include but not
limited to missing data due to unclassified cases by place of birth, inability to control for
other relevant covariates such as culture, preexisting health condition, and type of
healthcare system involved, lack of data collected for the duration of stay either in the
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United States or country of birth for the AFBB population and duration of prior out-ofU.S. stay for both the AMBB and AFBB.
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Chapter 4: Results
Introduction to data analysis and Results
In this chapter, I present quantitative analyses of the NSCLC cases in order to
profile the two study groups (AMBB and AFBB patients) and enable comparisons of
their demographic characteristics, stage at diagnosis, and treatments. I matched the
AMBB cases to the AFBB on their age and gender. I used a specific statistical tool and
techniques to investigate the research questions and hypotheses and to predict the
treatment type received. I also used logistic modeling. I performed the descriptive
statistics for both samples prior to and after the matching process. Furthermore, after
descriptive, Pearson’s chi-square are used to test the study’s four hypotheses and the chisquare value and the p-value are used to make decisions regarding the hypotheses. In
order to make a decision to either accept or reject the null hypotheses, I compared the
obtained p values to the alpha value of 0.05. Then, I estimated the binary logistic
regressions to investigate which factors best predicted surgical and radiation treatment.
Finally, I have presented a summary of the results at the end of the chapter.
Data Acquisition and Recoding. I used the SEER.STAT software to query the
data from the SEER-18 Registries database. The data query process was not
straightforward due to the large number of differential codes used for the cancer
histologic types and stages. I sought help from SEER by phone call and I asked for a
complete list of the codes and for help in transferring the queried dataset from the SEER
database into an Excel spread sheet. With the queried dataset, I recoded the age ranges,
marital status, surgical therapy, radiation therapy, the country of birth to align with the
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study questions. There were 135 AFBB and 25,139 AMBB. I eliminated 16 AFBB and
2846 AMBB cases because of missing values. This process yielded 119 AFBB and 22293
AMBB eligible cases using my study criteria, as outlined in Chapter 3. I then
recategorized participants using 10-year intervals. Table 2 shows the age distribution of
the cases. It excludes the 0-29 years old age group since that range had no AFBB cases.
My recoding produced 5 age categories: 30-39 years, 40-49 years, 50-59 years, 60-69
years, and >69 years. To provide more simplicity than that provided by SEER, I recoded
marital status into four categories: single, married, Divorced, and Widowed. I classified
the NSCLC stages at diagnosis as “Early Stage” (to include stages I and II) and “Late
stage” (to include stages III and IV). Also, I dichotomized the therapy types received
were surgery and radiation of which surgical therapy to “Yes”, if any of the 24 different
types of surgical procedures reported was received, and “No” if none of the 24 different
types was received. In the same way, I dichotomized radiation therapy to “Yes” to
incorporate any of the various forms of radiation procedures received, and “No” if no
form of radiation treatment was received. I renamed birth country as United States for
AMBB patients and Africa for AFBB patients. This categorization was simpler and easy
to understand the different groups and variables.
Sampling of Data. Among the 135 AFBB and 25139 AMBB SEER cases for
2004-2011, 16 AFBB and 2846 AMBB cases were missing some values. I eliminated
these cases from the study dataset, which left 119 AFBB and 22293 AMBB NSCLC
cases for the study sample. This left a study cohort with very large population ratio
difference. I then considered a 1 AFBB to 2 AMBB sampling to reduce the sample size
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difference and eliminate statistical differences that the large size difference would
influence. In this case, I considered age and gender as the prime confounding variables
and I used them for the match. Thus, I compared the age and gender distribution for
AFBB and AMBB prior to the sampling, in order to determine if there were any age and
gender distributions differences between the two groups prior to sampling.
Age distribution prior to sampling AMBB study subjects. For the 5 age groups
comparison, the result of the analysis is presented in Table 2 below.
Table 2 Age Distribution for AFBB and AMBB Study Subjects
Age (Years)

Birth country
AMBB

AFBB

p value

30-39

139 (1%)

7 (6%)

0.00*

40-49

1572 (7%)

12 (10%)

0.2

50-59

5229 (24%)

38 (32%)

0.03*

60-69

7100 (32%)

43 (36%)

0.32

> 69

8253 (37%)

19 (16%)

0.00*

Total

22293 (100%)

119 (100%)

Note. Percent values were rounded.
*p < 0.05
Table 2 shows that there is a significant difference in age categories. Of the five age
categories, three are significantly different between the AFBB and AMBB. AFBB
patients were comparatively younger than the AMBB patients.
Gender distribution prior to sampling AMBB study subjects. The result of
gender distribution is presented in Table 3 below. It shows that the gender distribution
between AMBB and AFBB patients was not significantly different.
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Table 3 Gender distribution for all AFBB and prior to sampling AMBB study subjects

Gender

Total

Birth Country (USA or Africa)
AMBB

AFBB

p-value

Female

9089(41%)

59(50%)

0.05

Male

13204(59%)

60(50%)

0.05

22293(100%)

119(100%)

Note. Percent values were rounded.
*p < 0.05
Conclusively, for the before sampling test for age and gender distribution, the analysis
found that the age distribution was significantly different between AMBB and AFBB
cases prior to the sampling. But, for gender, the distribution was not significantly
different. Table 3, shows that for AFBB the gender was 50% male and 50% female;
while for AMBB the gender was 59% male and 41% female; this difference in gender
distribution was not statistically significant. Random sampling for this study was then
performed based on this result. Due to the low frequency count of 119 for AFBB I made
a decision to include all 119 in the study. I did the sampling following the results of the
age and gender distribution tests. From the non-ordered original 22293 AMBB data I
selected the first 238 so as to provide 2 AMBB for each of the AFBB study subjects. I
entered the study cohort consisting of 119 AFBB cases and 238 AMBB cases into SPSS
and appropriately coded for the study hypotheses assessment tests.
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Descriptive Statistics.
Marital Status of the NSCLC cases. After recoding the marital status for this
study sample as “single”, “married”, “divorced” and ‘widowed”, I computed the NSCLC
disease frequency and percentages by marital status and presented the results in Table 4.
Among the AFBB patients, 25% were single, while 24% of AMBB were single, and there
is no significant difference between the two groups considering the single status.
However, about 35% of AMBB cases were married, while 57% of the AFBB were
married, this shows the proportion of AFBB cases that were married are higher, and there
is a significant difference in proportion for married cases between AFBB and AMBB
patients (p < 0.05).
Table 4 Marital Status of AMBB and AFBB Subjects

Single
Marrital Status

Birthplace (Africa or
USA)
AMBB
AFBB
57(24%)
30(25%)

p-value
0.78

Married

82(35%)

68(57%)

Divorced

54(23%)

8(7%)

<0.01*

Widowed

45(19%)

13(11%)

0.05

238(100%)

119(100%)

Total

<0.05*

Note. Percent values were rounded.
*p < 0.05
Table 4 also shows that for AFBB, about 7% were divorced while for AMBB 23% were
divorced patients. This indicates that the proportion of divorced AMBB patients is
considerably higher compared to AFBB, and these proportions are significantly different
(p < 0.05) as shown in Table 4. Finally, 11% of the AFBB patients were widowed and
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19% of AMBB were widowed, and these proportions were not significantly different as
shown on Table 4.
NSCLC Stage at diagnosis. The NSCLC stage at diagnosis by birth place is
presented in Table 5. Here, for AMBB patients 25% of the patients were at early stage,
while for AFBB it was 24%.
Table 5 NSCLC Stage at diagnosis by birth place (Africa or USA) for study subjects
Birth place (Africa or USA)

NSCLC Early Stage
Stage at
diagnosis Late stage

AMBB
60(25%)

P-value
0.72

178(75%)

91(77%)
0.72

238(100%)

Total

AFBB
28(24%)

119(100%)

Note. Percent values were rounded.
Critical value: p > 0.05
Also, 75% of the AMBB patients were diagnosed at late stage, while 77% of AFBB were
at late stage. The test of proportion for the NSCLC diagnosis at late stage shows that
there is no significant difference between AMBB and AFBB patients as presented on
Table 5.

Surgical Treatment. The patients received two types of therapies, surgery and
radiation. Table 6 illustrates the information regarding surgical therapy of the study
subjects data set. As presented, 29% of the AFBB patients received surgical therapy,
whereas 20% of the AMBB patients had surgical therapy as treatment, and these
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proportions are significantly different (p < 0.05). Furthermore, as presented on Table 6,
the proportion of AFBB patients that did not have surgery compared to the corresponding
proportion of AMBB patients were significantly different (p < 0.05). The same
conclusion applies to the proportions AFBB and AMBB that received surgical therapy (p
< 0.05) as shown on Table 6.
Table 6 Surgical therapy by birthplace (Africa or USA) for study subjects

Birth place

Surgical
Therapy

Total

AMBB

AFBB

P-value

No

191(80%)

84(71%)

0.04*

Yes

47(20%)

35(29%)

0.04*

238(100%)

119(100%)

Note. Percent values were rounded
*critical value: p < 0.05

Radiation Treatment. Table 7 shows that among AMBB patients 50% did not
receive radiation therapy, compared with a corresponding 63% of AFBB patients.
Statistically, these proportions are significantly different (p<0.05). Additionally, 37% of
the AFBB patients received radiation therapy compared with a corresponding 50% of the
AMBB patients. These proportions are significantly different (p < 0.05).
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Table 7 Radiation therapy by birthplace (Africa or USA) for study subjects
Birth place (Africa or USA)
AMBB
AFBB

P-value

No

118(50%)

75(63%)

0.02*

Yes

120(50%)

44(37%)

0.02*

238(100%)

119(100%)

Radiation
Therapy

Total

Note. Percent values were rounded
*critical value: p < 0.05

Hypotheses Testing.
Based on the four research questions (RQ), the null hypothesis (H0) and alternative
hypotheses (H1) for each corresponding RQ were formulated in order to objectively
answer the questions. The alpha or predetermined level of statistical significance in this
study was 0.05 to which all the p-values were compared to determine whether or not to
reject the null hypothesis. In each case, I used the Chi-square test of independence to
determine which hypothesis to accept and which to reject. The hypotheses test results are
discussed in this section.
In order to answer RQ1 and judge the hypotheses objectively, I applied the
Pearson Chi-Square Analysis. Table 8 presents the expected and observed counts for each
category of NSCLC stage for the AFBB and AMBB patients. I assessed the difference
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between the observed count and expected counts and then calculated the p-value for each
proportion. The result of Pearson Chi-Square Analysis is also presented in Table 8.

Table 8 Pearson Chi-Square to assess the difference in NSCLC Stage at Diagnosis for
AMBB and AFBB patients

Birth place (Africa or USA)
AMBB

NSCLC
Stage at
Diagnosis

AFBB

60(25%)

28(24%)

58.7

29.3

Count
Expected
Count

178(75%)

91(77%)

179.3

89.7

Count

238(100%)

119(100%)

Early
Stage

Count
Expected
Count

Late
stage
Total

p-value
0.72*

0.72*

Note. Percent values were rounded
Pearson Chi-Square, X2 = 0.1206
Degree of freedom = 1
*Critical Value: p > 0.05
The result of the Pearson Chi-Square test indicates that there is no significant difference
between the proportion of AFBB and AMBB diagnosed with NSCLC by stage (early and
late) and reported to SEER from 2004-2011.
To answer the RQ2 and assess the hypotheses objectively, I applied the Pearson
Chi-Square Analysis. Table 9 is the contingency table which presents the expected and
observed counts for each category by NSCLC early stage for the AFBB and AMBB
patients who underwent surgery.
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Table 9 Pearson Chi-Square to assess the differences between AMBB and AFBB patients
diagnosed with early stage NSCLC who received surgical therapy

Birth place (Africa or USA)

No
Surgical
Therapy

Yes

AMBB

AFBB

Count
Expected Count

28(47%)

6(21%)

23.2

10.8

Count

32(53%)

22(79%)

Expected Count

36.8

Total Count

60(100%)

p-value
0.02*

0.02*

19.7
28(100%)

Note. Percent values were rounded.
Pearson Chi-Square, X2 = 5.129
Degree of freedom = 1
*Critical Value: p < 0.05
Table 9 shows that there is a significant difference between the proportion of AFBB
diagnosed with early stage (I, II) NSCLC and the corresponding proportion of AMBB
patients who underwent surgery (p < 0.05). This means that the null hypothesis is
rejected and the alternative hypothesis is accepted. As a whole, for surgical therapy as
shown in Table 9, the proportion of AFBB patients who underwent surgery differs from
the corresponding proportion of AMBB patients (p < 0.05). AFBB patients were found to
be more likely to have received surgical therapy compared with AMBB patients.
To objectively answer RQ3 by assessing the hypotheses, I applied the cross-tab
Pearson Chi-Square tests, first to those that were diagnosed at the early as well as the late
stages and then to the overall disease stages at diagnosis, early and late combined.
Amongst the patients diagnosed with NSCLC at the early stages, there was a significant
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difference in the receipt of radiation therapy (p <0.05) between AMBB and AFBB. The
proportion of AMBB patients (37%) that received radiation treatment was higher
compared with the corresponding proportion of AFBB patients (14%) as shown on Table
10. But, for those diagnosed at the late stages of the disease, there was no significant
difference in the proportion of AMBB (55%) that received radiation therapy when
compared with the corresponding proportion of AFBB patients (44%) as shown on Table
11. When I compared the two groups for radiation treatment for the overall disease stages
at diagnosis, early and late combined the result of the analysis is summarized and
presented in Table 12. This Table 12 shows that per the Chi-Square analysis, the null
hypothesis is rejected since the proportion of AFBB NSCLC (stages I, II, III and IV)
patients treated with radiation therapy does differ significantly from the corresponding
proportion of AMBB patients, reported to SEER from 2004-2011 (p < 0.05).
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Table 10 Pearson Chi-Square to assess the difference in radiation therapy between
AMBB and AFBB patients diagnosed at early stage NSCLC

Birthplace (Africa or
USA)
AMBB
AFBB
38(63%)

24(86%)

42.3

19.7

Yes

Count
Expected Count

22(37%)
17.7

4(14%)
8.3

Total

Count

60(100%)

28(100%)

Count
Expected Count

No
Radiation Therapy
(early stage)

Note. Percent values were rounded.
Pearson Chi-Square, X2 = 4.594
Degree of freedom = 1
*Critical Value: p < 0.05
Table 11 Pearson Chi-Square to assess the difference in radiation therapy between
AMBB and AFBB patients diagnosed at late stage NSCLC

No
Radiation
Therapy (late
stage)
Yes

Count
Expected
Count
Count
Expected
Count

Total Count
Note. Percent values were rounded.
Pearson Chi-Square, X2 = 2.97
Degree of freedom = 1
*Critical Value: p > 0.05

Birthplace (Africa or
USA)
AMBB
AFBB
80(45%)
51(56%)
86.7

44.3

98(55%)

40(44%)

91.3

46.7

178 100%)

91(100%)

p-value
0.08*

0.08*

p-value
0.03*

0.03*
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Table 12 Pearson Chi-Square to assess the difference in radiation therapy between
AMBB and AFBB patients for all stages (Early and Late)

No
Radiation
Therapy
(all stages)

Count
Expected Count

Birthplace (Africa or
USA)
AMBB
AFBB
118(50%)
75(63%)
128.7
64.3

Count

120(50%)

44(37%)

Table 119.3

54.7

238(Table
110%)

119(Table
110%)

p-value
0.02*

0.02*

Yes
Expected Count
Total

Count

Note. Percent values were rounded.
Pearson Chi-Square, X2 = 5.77
Degree of freedom = 1
*Critical Value: p < 0.05

As presented in Table 12, among AMBB patients 50% did not receive radiation therapy,
compared to a corresponding 63% of AFBB patients. Statistically, these proportions are
significantly different (p < 0.05) as shown on Table 12with the corresponding 50% of the
AMBB patients; and this difference was found to be statistically significant (p < 0.05).
AMBB patients were more likely to receive radiation therapy at all the stages (I, II, III
and IV) of the NSCLC than AFBB patients.
For research question 4 (RQ 4), I queried the data and obtained a sample with
total of eight early stage (I, II) NSCLC patients who received neither surgery nor
radiation for both AFBB and AMBB. This was composed of 1 AFBB and 7 AMBB cases
as shown in the Appendix. The attempt to use any statistical tools to test the hypothesis
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was unsuccessful. Therefore, the hypotheses could not be tested and so the research
question was left unanswered.
Logistic Regression Analysis
In modeling the relation between treatment types and demographic variables in
relation to country of birth of the patients, I conducted the analysis for both surgical and
radiation treatment. I used the variables available on the SEER database that are possibly
responsible for influencing the receipt of surgery or radiation therapy as a treatment
choice for the analysis. These include age, gender, marital status, country of birth (Africa
or USA), and the stage at diagnosis for the NSCLC. For both surgery and radiation
treatments the regression results are discussed in the sections below.
Surgery treatment prediction. I performed a logistic regression analysis to
ascertain the effect of age, gender, marital status, country of birth, and stage at diagnosis
for the NSCLC in predicting the probability of a patient receiving surgery as treatment. In
this case, the dependent variable is the surgery, dichotomized into “No Surgery” and
“Surgery”. In the SPSS data analysis software I coded “No Surgery” as “1” and Surgery
as “2”. Meanwhile, I coded the independent variables as follows: age of the patient at
diagnosis (5 categories), gender (Female =1, Male =2), Marital Status (single = 1,
married = 2, divorced = 3 and widowed = 4), Country of birth (AMBB = 1, AFBB = 2),
and Stage at diagnosis (1= Early, 2 = Late). The result of the model is presented in
summary in Table 13 below.

48
Table 13 Logistic model summary for surgery treatment

Independent Beta
S.E.
Variables
(unstandardized)
Age
Gender
Marital
Status
Stage
Country of
birth (USA
or Africa)
Constant

95.0% CI for
EXP(B)

Sig./

-0.279
-0.335

0.156
0.309

1
1

Exp(B)
(AFBB/AMBB)
PLower Upper
value
0.075
0.757
0.557 1.028
0.278
0.716
0.391 1.31

0.023

0.163

1

0.89

1.023

0.743

1.408

-2.806

0.32

1

0

0.06

0.032

0.113

0.663

0.326

1

0.042

1.94

1.024

3.677

3.992

1.084

1

0

54.156

df

Note. Description of table labels
Model χ2 = 99.86, p<0.05
Mode df = 5
Pseudo R2 = 0.369
N = 357
The Beta (un- standardized) represents the coefficients for the independent variables.
S.E. is the standard error of the beta values;
Df is the degree of freedom,
Sig. is the p-value to show the significance of the independent variables in the model,
Exp (B), is the Odds Ratio (OR)
The logistic regression model was statistically significant (p < 0.05). The model
explained 36.9% of the variance (R2) in surgical treatment for the NSCLC.
In this model, stages at diagnosis and country of birth (USA or Africa) have significant
influence on the model (p < 0.05). In the model, the most important variable turns out to
be the stage at diagnosis which has a negative influence on the chance of a patient
receiving surgery, (OR (AFBB/AMBB) = 0.06; 95% CI 0.032-0.11) as shown on Table
13. This indicates that for one unit increase in stage variable (Early stage, to Late stage)
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here would be a 0.06 times reduction in the probability for a patient to receive surgery. In
other words, if the stage goes from early to late, there would be 94% reduction in the
likelihood of having surgery. This implies that late stage patients rarely ever have surgery
as a treatment choice, which is as expected, considering the guidelines or
recommendations for NSCLC treatment (National Cancer Institute, 2015; and National
Comprehensive Cancer Network, 2015). Also in this model, country of birth (USA or
Africa) has a positive beta value (OR (AFBB/AMBB) = 1.94; 95% CI 1.02-3.68) as
shown on Table 13. This means that AFBB patients would receive surgery about 1.94
times more compared to AMBB patients.
The summary of this regression analysis shows that the stage at diagnosis is one
important factor in determining if a patient will receive surgical treatment, with surgery
most likely to happen at early stage of NSCLC than at late stage. Furthermore, AFBB
patients are more likely to receive surgery compared to the AMBB patients.
Radiation treatment prediction. I performed another logistic regression analysis
to determine the effect of age, gender, marital status, country of birth, and the disease
stage in predicting the probability of a patient receiving radiation as treatment. In this
case, the dependent variable is radiation treatment, dichotomized as “No radiation”, and
“radiation”, respectively coded in SPSS as “0” and “1”. I entered the independent
variables, age (with 5 categories), gender (1 = Female, 2 = Male), Marital Status (single =
1, married = 2, divorced = 3 and widowed = 4), Country of birth (AMBB= 1, AFBB = 2)
and Stage (1= Early, 2 = Late) in the model. The result summary of the model is
presented in Table 14 below.
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Table 14 Logistic model summary for radiation treatment

0.019
0.082

0.113
0.225

1
1

0.88
0.71

1.019
1.086

95.0% CI for
EXP(B)
Lower Upper
0.817 1.272
0.699 1.688

0.087

0.116

1

0.46

1.091

0.869

1.37

0.947

0.267

1

0

2.578

1.528

4.35

-0.544

0.246

1

0.03

0.581

0.358

0.941

-1.512

0.845

1

0.07

0.22

Independent Beta
S.E.
Variables
(unstandardized)

Sig./P- Exp(B)
df value
(AFBB/AMBB)

Age
Gender
Marital
Status
Stage
at diagnosis
Country of
birth (USA
or Africa)
Constant

Note. Description of table labels
Model χ2 = 20.17
Model df = 5
n = 357
The logistic regression model was statistically significant, p < 0.05.
The model explains 7.3% of the variance in surgery probability based on the independent
variables.
The Beta (un- standardized) represents the coefficients for the independent variables.
S.E. is the standard error of the beta values;
df is the degree of freedom,
Sig. is the P-value to show the significance of the independent variables in the model,
Exp (B) is the Odds Ratio (OR)
In this particular model in predicting radiation treatment probability, Stage at diagnosis
and Country of birth (USA or Africa) are the variables that are significant as predictors
with the respective p-values of 0.00 and 0.03. The other 3 variables; age, gender, and
marital status are not statistically significant in predicting radiation treatment. The most
important variable in this model is the “Stage at diagnosis”, which has a positive
influence on receiving radiation as a form of treatment. Correspondingly, for early to late
stage, there would be 2.58 times increase in the probability of receiving radiation as
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treatment. This implies that late stage patients would have 2.58 times higher probability
of receiving radiation treatment than early stage. This is an expected result given the
NSCLC treatment guidelines or recommendations that early stage NSCLC patients
should get radiation therapy only when they cannot have surgery, or be treated by
radiation therapy in combination with surgery for clinical trial purposes (Howington,
Blum, Chang, Balekian, & Murthy, 2013). Meanwhile, the late stage disease patients are
to receive radiation therapy without any restrictions (National Cancer Institute, 2015).
Additionally, the country of birth (USA or Africa) of the patients in the model shows that
AMBB patients will receive radiation therapy more compared to AFBB patients. The
regression analysis for radiation treatment prediction indicates that, for radiation therapy
the patients are only dependent upon the stage of NSCLC and country of birth. Other
demographics included in the model (age, gender, marital status) were not predictive of
radiation treatment. Conclusively, at the late stage of NSCLC, there is very low
probability of receiving surgery; meanwhile there is higher probability for radiation
treatment, which is an expected result, following the NSCLC treatment guidelines or
recommendations (National Cancer Institute, 2015; and National Comprehensive Cancer
Network, 2015).
Results summary to the research questions.
Research Question 1. The results indicate that statistically there is no significant
difference in the proportions of AFBB and AMBB patients for the NSCLC stage (early
and late) at diagnosis as shown in Table 8.
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Research Question 2. The results show in Table 6 that the proportions of AFBB
patients who underwent surgery differ significantly from the corresponding proportion of
AMBB patients (p < 0.05), the AFBB patients were more likely to have surgical
treatment compared to AMBB patients. There are no previous studies available that
compared these two populations; therefore this result cannot be compared to any other
and so must be interpreted with caution.
Research Question 3. The analysis found a significant difference in the
proportion of AFBB NSCLC (stages I, II, III and IV) patients treated with radiation to the
corresponding proportion of AMBB patients (p < 0.05) as shown on Table 12, where the
AMBB patients were more likely to receive radiation therapy compared to AFBB
patients.
Research Question 4. Among the early stage (I, II) NSCLC patients reported to
SEER between 2004 and 2011, does the proportion of AFBB patients who received
neither surgery nor radiation differ significantly from the corresponding proportion of
AMBB patients? I did not perform any statistical analysis for this research question
because the subgroup sample counts were very low as shown in Appendix.
Regression model for surgery. In predicting surgery as a treatment, the stage at
diagnosis of the NSCLC is the most significant predictor followed by the country of birth
(USA or Africa). Patients diagnosed with early stage NSCLC have a higher probability of
receiving surgery as a treatment than those diagnosed at late stage of the disease, which is
as expected, given the recommendations for treatment of NSCLC patients (National
Cancer Institute, 2015; and National Comprehensive Cancer Network, 2015). In addition,
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The AFBB patients were younger than AMBB patients as shown on Table 2, and the
AFBB patients had a higher probability of getting surgery than AMBB patients (OR
[AFBB/AMBB] = 1.94; 95% CI 1.02-3.68) as shown on Table 13.
Regression model for radiation. The variable that seems to influence radiation
treatment more is the stage at diagnosis of the patient. In this case with diagnosis at late
stage, the NCSLC patients are administered radiation therapy more, compared to the
early stage which is an expected outcome due to the guidelines or recommendations for
which treatment is suitable for what stage of the disease (National Cancer Institute, 2015;
and National Comprehensive Cancer Network 2015). Also, the country of birth (USA or
Africa) is an important predictor; here the AMBB patients are more likely to receive
radiation therapy compared to AFBB patients. (OR [AFBB/AMBB] = 0.58; CI 0.36 –
0.94) as shown on Table 14. Other demographics tested showed no influence on
predicting the radiation therapy receipt.
Summary
In this chapter, I used descriptive, hypotheses and regression models to analyze the
NCSLC patient data. The study used all of the AFBB and a sample drawn from the
AMBB population for the analysis to obtain the statistical tests results. I obtained the
AMBB sample using a random sampling method after doing a comparative age and
gender proportions of the two groups void of those with missing data values. The study
found significant differences between the proportions of AMBB and AFBB NSCLC
cases (p < 0.05) in 3 out of the 5 age categories, as shown in Table 2. But, the difference
in gender distribution was not statistically significant as shown in Table 3. The study also
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modeled the relationship for different treatment methods (surgery and radiation) and
found that the stage at diagnosis and country of birth (USA or Africa) are important
predictors of surgical and radiation treatments options.
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Chapter 5: Discussion, Conclusions, and Recommendations
Strengths and Weaknesses
This study’s strength lies in comparison of NSCLC patients who are of the same
race, AFBB and AMBB. In conducting this study, I strove to increase the knowledge
about within-race similarities and differences in relation to where NSCLC patients were
born, in Africa or in the United States. I did not have access to some data including
socioeconomic status and health insurance, which are important factors for lung cancer
disease outcome (Elchoufaniz, et al, 2013). Thus, one limitation to this study is that I was
not able to test the effects of these factors on patients’ stage at diagnosis and treatment
they received. In addition, the sample size was limited by the number of AFBB that were
diagnosed with NSCLC from 2004-2011. The low sample size for AFBB was further
affected by the number of cases with missing dependent variable data which I eliminated
from the study. I ignored the probability sample that I initially calculated for this study of
the size discrepancy between the two groups, AFBB (n= 135) and AMBB (n = 22293).
Meanwhile, from the total AMBB population, I performed an approximate random
sampling to obtain the study sample size and thus preserving the representativeness of the
AMBB selected study sample. Thus, it made the study more valid given the assured
representativeness of the samples selected from the total AMBB (n = 22293) group. The
lack of adequate number of sample for each group of early stage (I and II) NSCLC
patients (AFBB = 1 and AMBB = 7) as shown on Appendix A that received neither
surgery nor radiation as asked in RQ 4 was a hindrance in answering the research
question.
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Conclusion
Using the chi-square tests and the logistic regression analysis, I found no
significant difference in the proportions of AFBB and AMBB patients at early and late
stages of NSCLC diagnosis. However, the proportions of AFBB patients who underwent
surgery differed significantly from the corresponding proportion of AMBB patients (p <
0.05; see Table 6). I also found a significant difference in the proportion of AFBB
NSCLC (stages I, II, III and IV) patients treated with radiation as compared to the
corresponding proportion of AMBB patients (p < 0.05). But, the difference between
AFBB and AMBB patients that received neither surgery nor radiation could not be
calculated because of low sample counts for the subgroups.
The logistic regression analysis for predicting treatment receipt showed that
AFBB patients had a slightly higher probability to receive surgery compared to AMBB.
This study found that the AFBB patients were younger than AMBB as shown on Table 2.
The logistic regression analysis (OR [AFBB/AMBB]) = 1.94; 95% CI 1.02-3.68) means
that the AFBB patients had a higher probability of having had surgery as shown on Table
13, where the stage at diagnosis and the country of birth (USA or Africa) were the best
predictors of a patient to receive surgical therapy. Since the AFBB patients are younger,
their diagnosis would be earlier. With the AFBB patients being younger implies that the
AMBB patients were older. This analysis showed that the AMBB patients were more
likely to have received radiation treatment compared with AFBB patients where the Stage
at diagnosis and Country of birth (USA or Africa) with respective p-values of 0.00 and
0.03 were the best predictors for a patient to receive radiation therapy as shown on Table
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14. Literature search revealed that there are no existing previous studies that compared
these two populations with respect to NSCLC stage at diagnosis and the treatment
received. Thus it is difficult to make a comparison of this study outcome to previous
study literature in that same context. But, in the context of treating the disease as it relates
to the age and the disease stage at diagnosis for the general population of NSCLC
patients, this study outcome is similar to results obtained by a number of studies. In one
study that analyzed SEER lung cancer in general by comparing the older patient
population to the younger ones the result showed that elderly patient population received
surgical treatment only at half the rate at which younger patient population did
(Owonikoko, Ragin, Belani, Oton, Gooding, Taioli, et al., 2007). In another study that
analyzed data from a regional cancer registry, 80.2% of younger patients had surgery for
NSCLC, compared with 55.8% of the elderly; while radiation treatment was administered
more often in the elderly patients (30.5%) compared with 14.0% of the younger patients
(Hillner, McDonald, Desch, Smith, Penberthy, & Retchin, 1998).
These findings are all consistent with expectations based upon NSCLC treatment
guidelines or recommendations (National Cancer Institute, 2015; National
Comprehensive Cancer Network, 2015). Researchers analyzing SEER data have found
that stage at diagnosis is similar for all age groups, from the young through the elderly
(Owonikokoet al., 2007). Their findings validate the finding in this study that even
though AFBB and AMBB patient populations are significantly different in their ages, the
stage at diagnosis of the diseases is not significantly different between them.
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Recommendations
Even though I did not find any significant differences among AFBB and AMBB NSCLC
patients for the stage at diagnosis, I recommend that further lung cancer studies involving
comparisons of these two groups be performed with a much larger sample of AFBB
patients. This would provide better insights to whether any within race differences do
exist between the two groups with a bigger sample size, essential for efficient planning
the prevention and management of the disease.
Other covariates that include profession, socioeconomic status, and health insurance
status were not available in the SEER database for all the years, 2004-2011 for both
groups. Since all the patients in the SEER database are de-identified for confidentiality
purposes, it was not possible to do any datalink to obtain information on these
unavailable covariates from institutions that diagnosed them with NSCLC. I could not
measure the effects of these variables on predicting the probability for the receipt of
surgery or radiation therapy as a treatment choice. Therefore, I recommend that
researchers conduct further studies with a larger AFBB sample. Future researchers may
consider conducting original research in partnership with diagnostic institutions instead
of using a secondary data source such as the SEERS dataset. In doing so, they may be
able include these covariates to test their effects in predicting the probability of a patient
receiving surgery as treatment.
Conclusively, while there was no significant difference between AFBB and AMBB for
the stage at diagnosis of the NSCLC, there were significant differences in each type of
treatment receipt. The two subgroups involved in this study are both of the same race
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and are resident in the same country and so race and current country of residence are not
likely causes for this observed treatment differences. Given that there were no significant
gender differences before the comparisons were done and that I controlled for age by
doing the approximate random sampling to obtain the study sample size, it means that
gender and age differences are not likely cause for the observed significant difference in
treatment receipt. While other likely cause for such significant difference are the same
and others have been controlled for, the country of birth was not controlled for in terms
of their early childhood experiences and so might have been the reason why such a
difference in treatment receipt is observed. Therefore, the ecological theory can be used
to explain the outcome of this study.
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Appendix : Sample and Population Characteristics
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Sample and Population Characteristics (continued)
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